ALUNBRIG

This brand name is authorized in Austria, Australia, Canada, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Japan, Lithuania, Netherlands, Poland, Romania, Singapore, Turkey, United Kingdom, United States

Active ingredients

The drug ALUNBRIG contains one active pharmaceutical ingredient (API):

1 Brigatinib UNII HYW8DB273J - BRIGATINIB

Brigatinib is a tyrosine kinase inhibitor that targets ALK, c-ros oncogene 1 (ROS1), and insulin-like growth factor 1 receptor (IGF-1R). It is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). Read about Brigatinib

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ALUNBRIG Film-coated tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR
ALUNBRIG Film-coated tablet	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01ED04		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01ED Anaplastic lymphoma kinase (ALK) inhibitors
Discover more medicines within L01ED04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 11974F, 11976H, 11980M, 11984R
Country: CA	Health Products and Food Branch	Identifier(s): 02479206, 02479214, 02479222, 02479230
Country: EE	Ravimiamet	Identifier(s): 1763490, 1781883, 1783201, 1783212, 1783223, 1783234, 1783245, 1783256, 1783267, 1783289, 1783290, 1806870
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1181264008, 1181264010, 1181264011, 1181264012
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 070285, 090597, 165823, 197613, 426670, 428410
Country: FR	Base de données publique des médicaments	Identifier(s): 60648770, 61066196, 62626993, 66949061
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 365898, 365918, 367938, 378508, 378509
Country: HK	Department of Health Drug Office	Identifier(s): 66119, 66120, 66121
Country: IE	Health Products Regulatory Authority	Identifier(s): 88987, 88988, 88995, 88996
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 8108, 8110
Country: JP	医薬品医療機器総合機構	Identifier(s): 4291069F1022, 4291069F2029
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1086610, 1086611, 1086612, 1086613, 1086614, 1086615, 1086616, 1086617, 1086618, 1086619, 1087058, 1087059
Country: NL	Z-Index G-Standaard	Identifier(s): 16753798
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 196045, 196053, 196061, 197238
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100416370, 100416387, 100416393, 100416980
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W65342001, W65342002, W65343001, W65343002, W65344001, W66552001
Country: SG	Health Sciences Authority	Identifier(s): 15658P, 15659P, 15660P, 15661P
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699456090110, 8699456090127, 8699456090134, 8699456090141, 8699456090158, 8699456090165, 8699456090172, 8699456090189, 8699456090219
Country: US	FDA, National Drug Code	Identifier(s): 63020-090, 63020-113, 63020-180, 76189-113